Congress 107 - HR 3966 - Genomic Science and Technology Innovation Act of 2002

Sponsor

Cosponsors

Topics

Capital investments Commercialization Congress Congressional reporting requirements Data banks Federal advisory bodies Finance and Financial Sector Gene therapy Genetic research Government Operations and Politics Health Human genetics Intellectual property Legislation Medical tests Patents Policy sciences Regulatory impact statements Research and development Science, Technology, Communications Technological innovations

Full Text

View Full Bill Text

Votes

Summary

Genomic Science and Technology Innovation Act of 2002 - Requires the Director of the Office of Science and Technology Policy to conduct, or contract with the National Academy of Sciences to conduct, a study that assesses the impact of Federal policies, including intellectual property policies, on the innovation process for genomic technologies.

Requires such study to: (1) identify and quantify the effects of innovation policy on genomic science and technology innovation; (2) consider alternative levels of intellectual property protection genomic materials may receive and the likely impact on each element of the innovation pipeline; and (3) assess the net impact of Federal innovative policies.

Actions

May 6, 2002

Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Mar 22, 2002

Referred to the Subcommittee on Research.
Mar 22, 2002

Referred to the Subcommittee on Environment, Technology, and Standards.
Mar 14, 2002

Referred to the Committee on Science, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 14, 2002

Sponsor introductory remarks on measure. (CR E353-355)
Mar 14, 2002

Introduced in House

Amendments

Related Bills